James Hattersley

James E. Hattersley currently serves as SVP, Business Development at Palatin Technologies (NYSE: PTN). Palatin's therapeutic categories of interest include anti-inflammatory, ophthalmology, and women's health with indications in other underserved categories under development.

Before Palatin, James served as SVP of Corporate Development at Mission Pharmacal (dermatology, urology, and women's health) and Santen (ophthalmology). Both Mission and Santen were preceded by his tenure as SVP Business Development at Adherium, a global digital health outcomes organization where James was directly responsible for establishing Adherium North America. Prior to Adherium, Mr. Hattersley held the position of Vice President of Business Development at Nektar Therapeutics. At Nektar, James managed business development, corporate alliances, and commercial partnerships having late stage clinical assets under development [oncology, ophthalmology, pain management]. Before Nektar, Mr. Hattersley served for several years as Vice President of Business Development at Sun Pharmaceutical Industries directly responsible for acquisitions and strategic partnerships in North America, and out-licensing of oncology, ophthalmology, CNS, and respiratory opportunities in Japan territory.

Mr. Hattersley has over 25 years of successful leadership experience in life sciences, with a proven track record of identifying and executing deals of significant value. During the course of his career James has successfully completed numerous revenue-generating transactions involving small, medium, and major biotech/pharma organizations. Mr. Hattersley completed graduate and undergraduate academic degrees in biochemistry and neurobiology, respectively, from the University of California. In addition, James successfully completed post-graduate financial analytics certification at University of Chicago GSB.